Related Experiment Video
Updated: Oct 13, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
Davis P Argersinger1, Sarah R Rivas1, Ashish H Shah1
1Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
H3K27M-mutant diffuse midline gliomas (DMGs) are rare childhood central nervous system tumors that carry a dismal prognosis. Thus, innovative treatment approaches are greatly needed to improve clinical outcomes for these patients. Here, we discuss current trends in research of H3K27M-mutant diffuse midline glioma. This review highlights new developments of molecular pathophysiology for these tumors, as they relate to epigenetics and therapeutic targeting. We focus our discussion on combinatorial therapies addressing the inherent complexity of treating H3K27M-mutant diffuse midline gliomas and incorporating recent advances in immunotherapy, molecular biology, genetics, radiation, and stereotaxic surgical diagnostics.
Insights
Innovative treatments are crucial for H3K27M-mutant diffuse midline gliomas (DMGs), rare pediatric brain tumors with poor outcomes. Research focuses on epigenetic targets and combinatorial therapies, integrating immunotherapy and advanced diagnostics.
Area of Science:
- Pediatric neuro-oncology
- Cancer epigenetics
- Central nervous system tumor research
Background:
- H3K27M-mutant diffuse midline gliomas (DMGs) are aggressive pediatric brain tumors with limited treatment options.
- The dismal prognosis necessitates novel therapeutic strategies.
- Understanding the molecular underpinnings is key to developing effective treatments.
Purpose of the Study:
- To review current research trends in H3K27M-mutant diffuse midline gliomas.
- To highlight advancements in molecular pathophysiology, epigenetics, and therapeutic targeting.
- To discuss the potential of combinatorial therapies for improving patient outcomes.
Main Methods:
- Review of recent scientific literature on H3K27M-mutant DMGs.
- Analysis of emerging epigenetic and molecular targets.
- Synthesis of information on novel therapeutic approaches, including immunotherapy, radiation, and surgical techniques.
Main Results:
- Significant progress in understanding the epigenetic landscape of DMGs.
- Identification of potential therapeutic vulnerabilities related to H3K27M mutation.
- Exploration of multi-modal treatment strategies combining targeted therapies with established interventions.
Conclusions:
- Combinatorial therapies hold promise for treating H3K27M-mutant DMGs.
- Integrating advances in molecular biology, genetics, and immunotherapy is essential.
- Further research is needed to translate these findings into improved clinical practice for pediatric brain tumors.
